

## HBM's Global Partnership with Pfizer Inc. Global License Agreement for HBM9033 (MSLN-Targeted ADC)

HBM HOLDINGS-B 02142.HK www.harbourbiomed.com

## **Global Collaboration to Maximize the Value of Novel Therapeutics**





Payments in the aggregate amount of US\$53 million upfront and near-term payments



Potential milestone payments based on certain pending development and commercial achievements of up to approximately US\$1.05 billion in aggregate



Tiered royalties on net sales up to high teens.





## HBM9033 (MSLN) Next-Gen Mesothelin ADC for Solid Tumors


#### Highlights

- Unique fully human antibody warhead with improved binding, internalization, blocking activity and less interference by sMSLN
- □ The 4th generation novel payload with tumor-specific cleavable linker and high serum stability
- □ Superior therapeutic window compared to other ADC technologies
- □ IND clearance in August 2023




#### Robust anti-tumor activities and better PK/PD profile observed in preclinical studies


#### Better efficacy than MMAE based ADC in mouse CDX model



#### Better efficacy than DXd based ADC in mouse CDX model




## Confirmed in-vivo stability of ADC shows minimal payload release in monkey



NONA

BIOSCIENCES


## Harbour BioMed: Leader in Global Biologic Therapeutics Innovation



CN USA AUS

The rapid advancement of a differentiated innovative global portfolio

### Nona Biosciences Leverages Industry-leading Technology Platforms to Empower Global Therapeutic Innovation



## Strong R&D Capability Enables Harbour Therapeutics to Realize the Commercial Value of Assets in Various Ways



HARBOUR BIOMED





和铂医药

微信扫描二维码, 关注我的公众号



诺纳生物 Nona Biosciences 微信扫描二维码,关注我的公众号



# THANK YOU





诺纳生物 Nona Biosciences 徽信扫描二维码,关注我的公众号

**和铂医药** 微信扫描二维码,关注我的公众号